SI9715: MLN9708


In stock


MLN9708 is a proteasome inhibitor. Much like Bortezomib, the active form of MLN9708 selectively and reversibly inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, with IC50 and Ki of 3.4 nM and 0.93 nM, respectively. MLN9708 is the prodrug form of MLN2238; the two compounds are also known as ixazomib citrate and ixazomib, respectively. Under physiological conditions, the boronic citrate ester is rapidly hydrolyzed to a boronic acid. Ixazomib has been used in combination therapy as a treatment for multiple myeloma, and studies indicate that it has the potential to treat other cancers as well.


Purity >99.6 (HPLC), NMR (conforms)
Quantity 5 mg
Molecular Weight 517.12 Da
Physical State Lyophilized powder
Solubility DMSO (103 mg/mL)
CAS No. 1201902-80-8
Storage 4°C, (-20°C Long term). The product can be shipped at room temperature.

Additional information



There are no reviews yet.

Be the first to review “SI9715: MLN9708”


  • Inhibition of chymotrypsin-like proteasome catalytic activity.
  • Cellular studies of proteasome inhibition.